Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the near-approval…

Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in…

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 million…

Back-to-back clinical failures have dealt further blows to efforts to treat Parkinson’s disease by targeting alpha-synuclein. Days after UCB reported the…

Astellas is continuing to strengthen its neurological disease gene therapy capabilities, handing Sangamo Therapeutics $20 million upfront to help bypass…

Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies. The life…

Alphabet spinoff SandboxAQ has raised more than $300 million to go toward developing AI applications across multiple areas including drug…

After its rare disease drug was rejected by the FDA in late November, Applied Therapeutics vowed to fight on with…

For the end of this year, Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting.…

Ring Therapeutics, a Flagship Pioneering-backed biotech developing new viral vectors for gene therapy delivery, has cut its staff by just…